New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations

Thorac Cancer. 2020 Mar;11(3):495-497. doi: 10.1111/1759-7714.13334. Epub 2020 Jan 28.

Authors

Weisan Zhang^{1

2}, Fengtan Li³, Wenyuan Gao¹

Affiliations

¹ School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
² Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, China.
³ Department of Radiology, Tianjin Medical University General Hospital, Tianjin, China.

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Mutation*
Prognosis
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors